IDiyas

For the Inventor, By the Inventor

Stow, MA, United States of America

Christopher Sean Straub

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 5.7

ph-index = 4

Forward Citations = 84(Granted Patents)


Location History:

  • Cambridge, MA (US) (2011 - 2013)
  • Stow, MA (US) (2008 - 2022)

Company Filing History:

goldMedal16 out of 3,923 
 
Novartis Ag
 patents
silverMedal3 out of 1,206 
 
Dana-farber-cancer Institute Inc.
 patents
where one patent can have more than one assignee

Years Active: 2008-2022

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 11382905 - Immunomodulation by IAP inhibitors (2022-07-12),
2. 10786491 - Immunomodulation by IAP inhibitors (2020-09-29),
3. 9750729 - Immunomodulation by IAP inhibitors (2017-09-05),
4. 8993523 - Dimeric IAP inhibitors (2015-03-31),
5. 8906936 - Pharmaceutical combination comprising co-administration of taxane and N-(1-cyclohexyl-2-{2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide or pharmaceutically acceptable salt(s) thereof (2014-12-09),
6. 8552003 - (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-4-(4-fluorobenzoyl)-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide, or pharmaceutically acceptable salts thereof and their uses (2013-10-08),
7. 8546336 - SMAC peptidometics useful as IAP inhibitors (2013-10-01),
8. 8445440 - Dimeric IAP inhibitors (2013-05-21),
9. 8338440 - Inhibitors of IAP (2012-12-25),
10. 8207183 - Inhibitors of IAP (2012-06-26),
11. 8058272 - Organic compounds (2011-11-15),
12. 8048886 - Substituted pyrazine-3-one-derivatives as IAP inhibitors (2011-11-01),
13. 8044209 - Pyrrolydine derivatives as IAP inhibitors (2011-10-25),
14. 7989441 - Organic compounds (2011-08-02),
15. 7932255 - 2-aminocarbonyl substituted piperazine or diaza-cyclic compounds as apoptosis protein inhibitors (lap) modulators (2011-04-26),

Title: Christopher Sean Straub: Innovator in Immunomodulation

Introduction

Christopher Sean Straub is a prominent inventor based in Stow, MA, with a remarkable portfolio of 16 patents. His work primarily focuses on immunomodulation, particularly through the use of IAP inhibitors. His innovative contributions have the potential to significantly impact the fields of cancer treatment, infection prevention, and autoimmune disorder management.

Latest Patents

Among his latest patents, Straub has developed methods involving immune adjuvants that contain IAP inhibitors, including Smac mimetics. These inventions provide pharmaceutical compositions and vaccines that incorporate an IAP inhibitor alongside an antigen. His methods aim to enhance immune responses through the administration of IAP inhibitors, offering new avenues for treating or preventing cancer, infections, and autoimmune disorders. Additionally, his work includes methods for potentiating cytokine or antibody production, showcasing his commitment to advancing medical science.

Career Highlights

Throughout his career, Straub has made significant strides in the pharmaceutical industry. He has worked with notable companies such as Novartis AG and Dana-Farber Cancer Institute Inc. His experience in these prestigious organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Leigh Zawel and Zhuoliang Chen. Their collaborative efforts have further enriched the research environment and fostered innovation in immunomodulation.

Conclusion

Christopher Sean Straub's contributions to immunomodulation through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…